Sumitomo Mitsui Financial Group Inc. lowered its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 42.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 474,844 shares of the medical equipment provider’s stock after selling 350,220 shares during the quarter. Sumitomo Mitsui Financial Group Inc.’s holdings in Boston Scientific were worth $20,727,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Natural Investments LLC boosted its stake in shares of Boston Scientific by 1.3% during the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after purchasing an additional 206 shares during the period. MGO One Seven LLC grew its holdings in shares of Boston Scientific by 1.9% in the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after purchasing an additional 260 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of Boston Scientific by 1.4% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,918 shares of the medical equipment provider’s stock worth $870,000 after buying an additional 268 shares during the period. Great Waters Wealth Management increased its stake in shares of Boston Scientific by 3.7% in the third quarter. Great Waters Wealth Management now owns 7,823 shares of the medical equipment provider’s stock worth $341,000 after buying an additional 276 shares during the period. Finally, Bfsg LLC increased its stake in shares of Boston Scientific by 3.7% in the third quarter. Bfsg LLC now owns 7,867 shares of the medical equipment provider’s stock worth $343,000 after buying an additional 284 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
BSX has been the subject of a number of recent analyst reports. Robert W. Baird upped their price target on shares of Boston Scientific from $50.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Sanford C. Bernstein decreased their price objective on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating on the stock in a research report on Thursday, October 29th. Finally, UBS Group lowered their price objective on shares of Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $61.43.
Check Out Our Latest Report on Boston Scientific
Boston Scientific Stock Performance
Shares of Boston Scientific stock opened at $41.96 on Friday. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $101.91. The firm has a market capitalization of $60.82 billion, a P/E ratio of 17.78, a P/E/G ratio of 1.29 and a beta of 0.60. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $43.83 and a two-hundred day simple moving average of $53.26.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the company posted $0.75 EPS. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
See Also
- Five stocks we like better than Boston Scientific
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
